Empagliflozin lowered the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and preserved ejection fraction, regardless of diabetes status.
Absolute Event Rate: 0% vs 0%
Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).
Anker et al. (Fri,) reported a other. Empagliflozin lowered the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and preserved ejection fraction, regardless of diabetes status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: